Perspectives on the clinical development of immunotherapy in prostate cancer.

about

Perspectives on the clinical development of immunotherapy in prostate cancer.

Item

http://www.wikidata.org/entity/Q55029444

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Perspectives on the clinical development of immunotherapy in prostate cancer.

@en

Perspectives on the clinical development of immunotherapy in prostate cancer.

@nl

type

Item

label

Perspectives on the clinical development of immunotherapy in prostate cancer.

@en

Perspectives on the clinical development of immunotherapy in prostate cancer.

@nl

prefLabel

Perspectives on the clinical development of immunotherapy in prostate cancer.

@en

Perspectives on the clinical development of immunotherapy in prostate cancer.

@nl

P1476

Perspectives on the clinical development of immunotherapy in prostate cancer.

@en

P2093

James L Gulley

http://www.w3.org/2001/XMLSchema#string

Lisa M Cordes

http://www.w3.org/2001/XMLSchema#string

Ravi A Madan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

P304

253-259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.4103/AJA.AJA_9_18

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29582792

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

prostate cancer

Ipilimumaab

cell surface receptor

P932

5952479

http://www.w3.org/2001/XMLSchema#string